THE ANTI-TUBERCULOSIS ANTIBIOTIC OF RIFAPENTINE: PERSPECTIVES OF CLINICAL USE
Anti-tuberculosis chemotherapy makes a main component of therapy and involves the long-term treatment with the optimal combination of drugs. Tuberculosis incidence has been noted to be high in the risk groups (those receiving immunosuppressive therapy, people living with HIV, etc.); such patients are treated for their main disease in addition to anti-tuberculosis chemotherapy. A large number of drugs used simultaneously in treatment regimens can reduce patient's adherence to treatment, deteriorate drug tolerance and increase the frequency of adverse reactions. Using slow-release drugs within treatment regimens is one of the ways to reduce polypragmasy. One of them is rifapentine, recommended in the Russian Federation for the treatment of latent tuberculosis infection in patients with HIV infection. The review presents information about the efficacy, tolerability and safety of rifapentine within treatment regimens for active and latent tuberculosis infection.